1-3 of 3
Yajuan Qin
Close
Sort by
Journal Articles

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Clinical Trials & Observations
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo-Stella, Juan Pablo Alderuccio, Brad Kahl, Ying Wang, Yajuan Qin, Zhiying Cindy Xu, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2023) 8 (1): 93–98.
https://doi.org/10.1182/bloodadvances.2023010636
Published: 2023
Includes: Supplemental data
Journal Articles

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Clinical Trials & Observations
Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4736–4739.
https://doi.org/10.1182/bloodadvances.2022007782
Published: 2022
Journal Articles

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Clinical Trials & Observations
Nitin Jain, Wendy Stock, Amer Zeidan, Ehab Atallah, James McCloskey, Leonard Heffner, Benjamin Tomlinson, Bhavana Bhatnagar, Jay Feingold, David Ungar, Grace Chao, Xiaoyan Zhang, Yajuan Qin, Karin Havenith, Hagop Kantarjian, Matthew J. Wieduwilt
Journal: Blood Advances
Blood Adv (2020) 4 (3): 449–457.
https://doi.org/10.1182/bloodadvances.2019000767
Published: 2020
Includes: Supplemental data